Dapagliflozin - new solution in chronic kidney disease treatment

Maciej Bara; Jakub Starownik; Jakub Szydło; Patryk Gryszkiewicz; Jakub Nieznański

doi:10.56782/pps.195

Published : 2024-06-05

Vol. 22 No. 2 (2024)

Dapagliflozin - new solution in chronic kidney disease treatment

Maciej Bara

Jakub Starownik

Jakub Szydło

Patryk Gryszkiewicz

Jakub Nieznański

DOI: https://doi.org/10.56782/pps.195

Abstract

Despite being developed relatively recently, sodium-glucose cotransporter 2 (SGLT2) inhibitors have proven to be versatile pharmaceuticals useful in treatment of diabetes mellitus, heart failure and chronic kidney disease. Extensive and ongoing studies confirm more and more of their beneficial effects on metabolic, cardiovascular and renal health. Most of the conducted studies focused on patients suffering from diabetes mellitus type 2. Recent study, DAPA - CKD, published in the New England Journal of Medicine, confirmed the beneficial effect of dapagliflozin on chronic kidney disease of any etiology. This discovery has cemented flozins’ status as nephroprotective drugs and led to a new indication of use for dapagliflozin - chronic kidney disease. In Poland treatment of chronic kidney disease with dapagliflozin is reimbursed in patients with chronic kidney disease with estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m², albuminuria or proteinuria who were treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) for ≥4 weeks or with contraindications for ACEi/ARB therapy. Due to reimbursement, dapagliflozin therapy is financially available for a wide population of patients and, in light of recent discoveries, should be considered by clinicians.

Keywords:

dapagliflozin, chronic kidney disease, SGLT2i, nephrology

Most read articles by the same author(s)

Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
Maciej Bara, Agata Janczak, Toxicity of anesthetic gases: exposure in operating rooms and influence on the environment , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Bara, M., Starownik, J., Szydło, J., Gryszkiewicz, P., & Nieznański, J. (2024). Dapagliflozin - new solution in chronic kidney disease treatment. Prospects in Pharmaceutical Sciences, 22(2), 59–64. https://doi.org/10.56782/pps.195

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Mende, C.W. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Adv. Ther. 2022, 39(1), 148-164. DOI: 10.1007/s12325-021-01994-2 DOI: https://doi.org/10.1007/s12325-021-01994-2

Rieg, T.; Vallon, V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia 2018, 61(10), 2079-2086. DOI: 10.1007/s00125-018-4654-7 DOI: https://doi.org/10.1007/s00125-018-4654-7

Jasleen, B.; Vishal, G.K.; Sameera, M.; Fahad, M.; Brendan, O.; Deion, S.; Pemminati S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk. Cureus. 2023, 15(1), Art. No: e33939. DOI: 10.7759/cureus.33939 DOI: https://doi.org/10.7759/cureus.33939

Lee, P.C.; Ganguly, S.; Goh, S.Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. Obes. Rev. 2018, 19, 1630–1641. DOI: 10.1111/obr.12755. DOI: https://doi.org/10.1111/obr.12755

Thomas, M.C.; Cherney, D.Z.I. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 2018, 61, 2098–2107. DOI: 10.1007/s00125-018-4669-0. DOI: https://doi.org/10.1007/s00125-018-4669-0

Heerspink, H.J.; Perkins, B.A.; Fitchett, D.H. et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016, 134, 752–772. DOI: 10.1161/CIRCULATIONAHA.116.021887 DOI: https://doi.org/10.1161/CIRCULATIONAHA.116.021887

Sano, M.; Takei, M.; Shiraishi, Y.; Suzuki, Y. Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys. J. Clin. Med. Res. 2016, 8(12), 844-847 DOI: 10.14740/jocmr2760w DOI: https://doi.org/10.14740/jocmr2760w

Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; Cannon, C.P.; Capuano, G.; Chu, P.L.; de Zeeuw, D.; Greene, T.; Levin, A.; Pollock, C.; Wheeler, D.C.; Yavin, Y.; Zhang, H.; Zinman, B.; Meininger, G.; Brenner, B.M.; Mahaffey, K.W.; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019, 380(24), 2295-2306. DOI: 10.1056/NEJMoa1811744 DOI: https://doi.org/10.1056/NEJMoa1811744

Webster, A.C.; Nagler, E.V.; Morton, R.L.; Masson, P. Chronic Kidney Disease. Lancet 2017, 389(10075), 1238-1252. DOI: 10.1016/S0140-6736(16)32064-5 DOI: https://doi.org/10.1016/S0140-6736(16)32064-5

Stevens, L.A.; Schmid, C.H.; Greene, T.; Zhang, Y.L.; Beck, G.J.; Froissart, M.; Hamm, L.L.; Lewis, J.B.; Mauer, M.; Navis, G.J.; Steffes, M.W.; Eggers, P.W.; Coresh, J.; Levey, A.S. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am. J. Kidney Dis. 2010, 56(3), 486-95. DOI: 10.1053/j.ajkd.2010.03.026 DOI: https://doi.org/10.1053/j.ajkd.2010.03.026

Delanaye, P.; Cavalier, E.; Pottel, H.; Stehlé, T. New and old GFR equations: a European perspective. Clin. Kidney J. 2023, 16(9), 1375-1383. DOI: 10.1093/ckj/sfad039 DOI: https://doi.org/10.1093/ckj/sfad039

Michels, W.M.; Grootendorst, D.C.; Verduijn, M.; Elliott, E.G.; Dekker, F.W.; Krediet, R.T. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin. J. Am. Soc. Nephrol. 2010, 5(6), 1003-9. doi: 10.2215/CJN.06870909 DOI: https://doi.org/10.2215/CJN.06870909

KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Avaliable online: https://www.kidney-international.org/article/S0085-2538(20)31270-9/fulltext#secsectitle0015 (accessed on March 13, 2024)

MacRae, C.; Mercer, S.W.; Guthrie, B.; Henderson, D. Comorbidity in chronic kidney disease: a large cross-sectional study of prevalence in Scottish primary care. Br. J. Gen. Pract. 2021, 71(704), Art. No: e243-e249. DOI: 10.3399/bjgp20X714125 DOI: https://doi.org/10.3399/bjgp20X714125

Hill, N.R.; Fatoba, S.T.; Oke, J.L.; Hirst, J.A.; O'Callaghan, C.A.; Lasserson, D.S.; Hobbs, F.D. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One 2016, 11(7), Art. No: e0158765. DOI: 10.1371/journal.pone.0158765 DOI: https://doi.org/10.1371/journal.pone.0158765

Turin, T.C.; Tonelli, M.; Manns, B.J.; Ravani, P.; Ahmed, S.B.; Hemmelgarn, B.R. Chronic kidney disease and life expectancy. Nephrol. Dial. Transplant. 2012, 27(8), 3182-6. DOI: 10.1093/ndt/gfs052 DOI: https://doi.org/10.1093/ndt/gfs052

Kovesdy, C.P. Epidemiology of chronic kidney disease: an update 2022. Kidney Int. Suppl. 2022, 12(1), 7-11. DOI: 10.1016/j.kisu.2021.11.003 DOI: https://doi.org/10.1016/j.kisu.2021.11.003

Bailey, C.J.; Day, C.; Bellary, S.; Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr. Diab. Rep. 2022, 22(1), 39-52. https://doi.org/10.1007/s11892-021-01442-z DOI: https://doi.org/10.1007/s11892-021-01442-z

Yau, K.; Dharia, A.; Alrowiyti, I.; Cherney, D.Z.I. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations. Kidney Int. Rep. 2022, 7(7), 1463-1476. DOI: 10.1016/j.ekir.2022.04.094 DOI: https://doi.org/10.1016/j.ekir.2022.04.094

Charakterystyka Produktu Leczniczego - Forxiga. Available Online: https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf (accessed on March 10, 2024).

Heerspink, H.J.L.; Stefánsson, B.V.; Correa-Rotter, R.; Chertow, G.M.; Greene, T.; Hou, F.F.; Mann, J.F.E.; McMurray, J.J.V.; Lindberg, M.; Rossing, P.; Sjöström, C.D.; Toto, R.D.; Langkilde, A.M.; Wheeler, D.C; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2020, 383(15), 1436-1446. DOI: 10.1056/NEJMoa2024816 DOI: https://doi.org/10.1056/NEJMoa2024816

Herrington, W.G.; Staplin, N.; Wanner, C.; Green, J.B.; Hauske, S.J.; Emberson, J.R.; Preiss, D.; Judge, P.; Mayne, K.J.; Ng, S.Y.A.; Sammons, E.; Zhu, D.; Hill, M.; Stevens, W.; Wallendszus, K.; Brenner, S.; Cheung, A.K.; Liu, Z.H.; Li, J.; Hooi, L.S.; Liu, W.; Kadowaki, T.; Nangaku, M.; Levin, A.; Cherney, D.; Maggioni, A.P.; Pontremoli, R.; Deo, R.; Goto, S.; Rossello, X.; Tuttle, K.R.; Steubl, D.; Petrini, M.; Massey, D.; Eilbracht, J.; Brueckmann, M.; Landray, M.J.; Baigent, C.; Haynes, R. Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2023, 388(2), 117-127. DOI: 10.1056/NEJMoa2204233 DOI: https://doi.org/10.1056/NEJMoa2204233

Liu, J.; Cui, J.; Fang, X.; Chen, J.; Yan, W.; Shen, Q.; Xu, H. Efficacy and Safety of Dapagliflozin in Children With Inherited Proteinuric Kidney Disease: A Pilot Study. Kidney Int. Rep. 2021, 7(3), 638-641. DOI: 10.1016/j.ekir.2021.12.019 DOI: https://doi.org/10.1016/j.ekir.2021.12.019